Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models

SIMPLE SUMMARY: We investigated the effects of chemotherapeutics used for the frontline treatment of newly diagnosed high-risk neuroblastoma patients in combination with anti-GD2 antibody ch14.18/CHO (dinutuximab beta, DB) in the presence of immune cells in preclinical models of neuroblastoma. The c...

Descripción completa

Detalles Bibliográficos
Autores principales: Troschke-Meurer, Sascha, Zumpe, Maxi, Meißner, Lena, Siebert, Nikolai, Grabarczyk, Piotr, Forkel, Hannes, Maletzki, Claudia, Bekeschus, Sander, Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913527/
https://www.ncbi.nlm.nih.gov/pubmed/36765861
http://dx.doi.org/10.3390/cancers15030904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913527/
https://www.ncbi.nlm.nih.gov/pubmed/36765861
http://dx.doi.org/10.3390/cancers15030904

Ejemplares similares